Alex Ballinger

It is a pleasure to serve under your chairship, Dr Murrison. I will begin with testimony from two constituents. Angela Duffill lost her dad to prostate cancer in 2019. She speaks warmly of the 20 years of NHS care he received at Russells Hall hospital, but she also writes of the time before his diagnosis, when he was sitting on his symptoms and suffering in silence, not knowing what was wrong and not going to the doctor to find out. The familiar mix of embarrassment, stoicism and a public-spirited reluctance to waste NHS time is all too common among men of his age. Angela wonders whether a comprehensive, better publicised screening programme would have encouraged her dad to seek help sooner. Another constituent, Mervyn Jackson, wrote to me with his story. As prostate cancer ran in his family, he was encouraged to have regular tests. In 2021, those tests detected the cancer while he was still at an early stage. Mervyn said: “The worrying thing is that I had no symptoms at all from the cancer.” At the time of diagnosis, he felt completely well. There was nothing to tell him that he needed treatment, and nothing to prompt him to get tested, which he would not have done had it not been recommended based on his congenital risk. Following a successful round of radiotherapy, Mervyn is now 78 and in good health, living a full and active life. When we discuss early diagnosis, that is the possibility we are talking about—finding cancer while there is still time to treat it, potentially giving someone decades more of life. I welcome the Government’s decision to introduce targeted screening for men with the BRCA2 gene and a relevant family history of cancer, but many families will still be left asking where current policies leave them. I hope the Minister will recognise the urgency behind these concerns, and the need to keep wider screening under review and give families clear guidance while that work continues.